삼천당제약
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| 매출액 | 167,274,903,875 | 177,335,410,013 | 192,668,515,628 | 210,923,804,522 | 231,805,277,738 | KRW |
| 영업이익 | -15,293,087,301 | 12,224,651,499 | 9,559,814,333 | 2,641,971,274 | 8,466,512,950 | KRW |
| 당기순이익 | -16,555,159,161 | 5,837,527,768 | -10,382,721,091 | -10,916,104,966 | 5,261,822,741 | KRW |
| 자본총계 | 174,094,704,089 | 173,740,958,933 | 220,498,640,040 | 266,105,335,241 | 276,019,546,060 | KRW |
| 부채총계 | 93,647,148,966 | 127,634,262,627 | 109,561,750,075 | 170,368,051,944 | 197,638,158,783 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 53.79 | 73.46 | 49.69 | 64.02 | 71.60 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 210,500
- 80%
- 189,841.24 ~ 237,247.09
- 90%
- 183,355.65 ~ 251,788.65
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-08Filing title as filed[기재정정]반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-10-08Filing title as filed[기재정정]분기보고서 (2026.03) original ↗Source: dart_disclosure
- 2026-10-01Filing title as filed[기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-05Filing title as filed[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험) original ↗Source: dart_disclosure
- 2026-08-05Filing title as filed[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험) original ↗Source: dart_disclosure
- 2026-07-23Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-06-30Filing title as filed임시주주총회결과 original ↗Source: dart_disclosure
- 2026-06-30Filing title as filed독립이사의선임ㆍ해임또는중도퇴임에관한신고 original ↗Source: dart_disclosure
- 2026-06-12Filing title as filed주주총회소집공고 original ↗Source: dart_disclosure
- 2026-06-10Filing title as filed기업설명회(IR)개최 original ↗Source: dart_disclosure
- 2026-06-04Filing title as filed[기재정정]사업보고서 (2025.12) original ↗Source: dart_disclosure
- 2026-05-29Filing title as filed투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험) original ↗Source: dart_disclosure
- 2026-05-15Filing title as filed분기보고서 (2026.03) original ↗Source: dart_disclosure
- 2026-04-27Filing title as filed주주명부폐쇄기간또는기준일설정 original ↗Source: dart_disclosure
- 2026-04-27Filing title as filed주주총회소집결의 (임시주주총회) original ↗Source: dart_disclosure
- 2026-04-27Filing title as filed독립이사의선임ㆍ해임또는중도퇴임에관한신고 original ↗Source: dart_disclosure
- 2026-04-20Filing title as filed불성실공시법인지정 (공시불이행) original ↗Source: dart_disclosure
- 2026-04-16Filing title as filed[기재정정]기업설명회(IR)개최 original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…